Cyclacel Pharmaceuticals, INC. (BGMSP) — DEF 14A Filings
All DEF 14A filings from Cyclacel Pharmaceuticals, INC.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
Cyclacel Pharma Files DEF 14A on Exec Comp & Stock Awards
— Apr 24, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed a DEF 14A on April 24, 2025, detailing executive compensation and stock option awards for the fiscal years ending December -
Cyclacel Pharma Files 2025 Proxy Statement
— Jan 21, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on January 21, 2025, for its annual meeting on February 6, 2025. The filing details -
Cyclacel Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders
— May 8, 2024 Risk: low
Cyclacel Pharmaceuticals, Inc. (BGMSP) filed a Proxy Statement (DEF 14A) with the SEC on May 8, 2024. The 2024 Annual Meeting of Stockholders for Cyclacel Pharm
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX